Senior Staff Researcher/Team leader, Directeur de Recherche classe 2 (DR2) at the
Institut national de la santé et recherche médicale (Inserm)
UMRS 872 Equipe 21 : Ocular degenerative and neovascular processes
Centre de Recherche des Cordeliers
15, rue de l’école de médecine, 75006 Paris
2009 : Creation of the Equipe 21 : Ocular degenerative and neovascular processes
at the Centre de Recherche des Cordeliers
2008 : « Directeur de Recherche classe 2 » Inserm promotion
2007 : Habilitation à Diriger des Recherches Université Paris 5
2005 : « Chargé de Recherche classe 1 » Inserm (staff researcher) recruitment
2002-2005 : Post doctorat: Pharmacology, Hôpital Ste Justine, Montréal, Sylvain Chemtob.
2002: Ph.D. in molecular and cellular biology Université Paris 5.
2001: Doctor Medizinae. Magna cum laude. Charité, Université d‘Humboldt, Berlin.
1999: DEA in “Biologie et Pharmacologie de l`Hémostase et des Vaisseaux“.
1996: 3rd Staatsexamen (Final Medical State Exam) Munich, Germany.
1996-97: Department of Ophthalmology Charité, Humboldt University, Berlin (Resident / Interne).
Age-related Macular Degeneration (AMD) is the leading cause of legal blindness in industrialized countries. The pathology is characterized by lesions of photoreceptors, retinal pigment epithelium (RPE), Bruch’s membrane (BM) and choriocapillaris. There are two clinical forms of late AMD: the fast progressive “wet” form defined by choroidal neovascularisation, responsible for the most part of legal blindness in AMD and the more slowly progressf “atrophic” form characterized by RPE atrophy, photoreceptor degeneration and choroidal involution and obliteration.
It has been recognized that macrophages and microglial cells are activated in AMD lesions. Others and our group has shown that they and accumulate in the photoreceptor cell layer that is physiologically devoid of Macrophages and microglial cells.Macrophages are together with the retinal pigment epithelium main VEGF producers and their inhibition significantly inhibits choroidal neovascularization in animal models. Moreover, the prolonged presence of macrophages in the subretinal space is associated with photoreceptor degeneration. The goal of my group is to decipher mechanisms involved in angiogenesis, neovascularization and retinal degeneration with an emphasis on macrophages and microglial cells with the goal to identify new drug targets to treat neovascular and more importantly atrophic AMD.